Schedule 13G ownership disclosure
Enliven Therapeutics Inc
Common Stock · CUSIP: 29337E102
Event date: 2025-06-30
- Filing-level shares
- 2,941,395
- Percent of class
- 5.1%
- BlackRock, Inc.
Shares: 2,941,395 · Class: 5.1%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0002052113-25-003029
- Form type
- SCHEDULE 13G/A
- Filer
- BlackRock, Inc.
- CIK
- CIK 2012383
- Filed
- Jul 17, 2025
- Reporting period
- Jun 30, 2025
- Description
- Schedule 13G beneficial ownership